Scilex Holding Company — Company profile
Healthcare · Drug Manufacturers - General · United States
Last price 1.85 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 13.01M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.
Details
| Name | Scilex Holding Company |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Employees | 34 |
| Founded | 2011 |
| Ceo | Henry Ji |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US80880W2052 |
| Cusip | 80880W205 |
| Cik | 1820190 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Henry H. Ji Ph.D. | Chief Executive Officer, President and Executive Chairman |
| Stephen Ma | Senior Vice President, Chief Financial Officer, Chief Operating Officer, Corporate Secretary and Director |
| Dr. Suketu D. Desai Ph.D. | Interim Chief Technical Officer and Senior Vice President |
| Gigi DeGuzman | Vice President and Chief People Officer |
| Suresh K. Khemani | Senior Vice President, Chief Commercial Officer and GM of Scilex Pharma |
| Dr. Dmitri V. Lissin M.D. | Senior Vice President of Clinical Development and Medical Affairs and Interim Chief Medical Officer |
Contact
| Address | 960 San Antonio Road, Palo Alto, California 94303, United States |
| Phone | 650 516 4310 |
| Website | https://www.scilexholding.com |